TSXV:SQD.H - Post by User
Post by
FactFinder1994on Jun 02, 2023 12:09pm
133 Views
Post# 35477059
TOR-dx has been well planned by UHN (Dr. SHAF) and is key...
TOR-dx has been well planned by UHN (Dr. SHAF) and is key...to greater volume and success. Lung Bioengineering is well situated as a long term partner of UHN and has fully enrolled its pivotal confirmatory trial with the FDA for EVLP CLES. UHN is very much a part of the effort and so too will TOR-dx be included in protocol upon final approval.
LBE (United Therapeutics), a $10B market cap company stands to benefit greatly with the intigrated use of EVLP CLES inclusive of TOR-dx.
Ex Vivo Lung Perfusion (EVLP) is becoming the established standard of care for conditioning donor lungs suspected of injury prior to transplantation. Placing donor lungs on EVLP has been shown to increase the utilization of available lungs for transplant from 20% to 40%*. The criteria for selecting lungs for transplant after EVLP is currently based primarily on lung functionality and surgical team experience and expertise. To date, there are no quantitative inflammatory biomarker data to assist surgical decision-making regarding lung quality.